MARKET

HCM

HCM

Chi-Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.80
-0.65
-2.13%
After Hours: 29.80 0 0.00% 16:38 02/25 EST
OPEN
30.83
PREV CLOSE
30.45
HIGH
31.51
LOW
29.50
VOLUME
260.10K
TURNOVER
--
52 WEEK HIGH
37.00
52 WEEK LOW
14.74
MARKET CAP
4.34B
P/E (TTM)
-364.3032
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global Dental Drug Market 2020 by Key Players, Regions, Type and Application, Forecast to 2025
Feb 16, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz proclaims the addition of a new report titled Global Dental Drug Market 2020 by...
CDN Newswire · 02/17 02:32
CPP Investments Net Assets Total $475.7 Billion at Third Quarter Fiscal 2021
CPP Investments Net Assets Total $475.7 Billion at Third Quarter Fiscal 2021
CNW Group · 02/11 13:01
Chi-Med to Announce 2020 Final Results
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 1...
GlobeNewswire · 02/03 07:00
Chi-Med to Announce 2020 Final Results
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 1...
GlobeNewswire · 02/03 07:00
Chi-Med to Announce 2020 Final Results
Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am Eastern Sta...
GlobeNewswire · 02/03 07:00
Global Dental Drug Market 2020 Top Industry Trend and Segments Analysis upto 2025
Jan 20, 2021 (CDN Newswire via Comtex) -- Global Dental Drug Market 2020 by Manufacturers, Type and Application, Forecast to 2025 focuses on showing high-end...
CDN Newswire · 01/20 22:47
Dental Drug Market 2021 Growth Analysis, Share, and consumption by Regional data, Investigation and Growth, Demand by Regions, Types and Analysis of Key Players- Research Forecasts To 2024
Jan 17, 2021 (The Expresswire) -- Dental Drug Market provides detailed analysis of Market Overview, Drivers, Prospects, Potential Application. Also Dental...
The Express Wire · 01/18 03:42
Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presented at the upcoming virtual 2020 World Conference on Lung Cancer (WCLC 2020), taking ...
GlobeNewswire · 01/14 10:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HCM. Analyze the recent business situations of Chi-Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HCM stock price target is 39.60 with a high estimate of 45.00 and a low estimate of 29.91.
EPS
Institutional Holdings
Institutions: 169
Institutional Holdings: 51.42M
% Owned: 35.33%
Shares Outstanding: 145.54M
TypeInstitutionsShares
Increased
50
1.56M
New
18
317.75K
Decreased
34
1.03M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Director
Simon To
Chief Executive Officer/Executive Director/IR Contact Officer
Christian Hogg
Chief Financial Officer/Executive Director
Chig Fung Cheng
Executive Director
Weiguo Su
Secretary/Non-Executive Director
Edith Shih
Non-Executive Director
Dan Eldar
Non-Executive Independent Director
Paul Carter
Non-Executive Independent Director
Karen Ferrante
Non-Executive Independent Director
Graeme Jack
Non-Executive Independent Director
Shu Kam Mok
  • Dividends
  • Splits
  • Insider Activity
No Data
About HCM
Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.

Webull offers kinds of Hutchison China MediTech Limited stock information, including NASDAQ:HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.